Answer
Ravulizumab, an IgG monoclonal antibody, is expected to be metabolised like endogenous IgG through catabolic degradation into small peptides and amino acids, and has no known active metabolites.
Sources for this answer
- Ultomiris 300 mg/3 mL and 1100 mg/11 mL PLGB 31187/0007Alexion Pharma UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 12Document updated
Sources checked